Conditions: Osteoarthritis of the Knee
Keywords: Osteoarthritis Celecoxib Etoricoxib
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 239
Healthy volunteers: no

Brief summary:
The main purpose of this study is to establish that etoricoxib 30 mg is safe and not inferior to celecoxib 200 mg in the treatment of the signs and symptoms of osteoarthritis in Korean patients. Given that the efficacy of etoricoxib vs. placebo in the treatment of osteoarthritis has been established, and that prescription drugs, such as celecoxib, are available for the treatment of pain associated with osteoarthritis in Korea, it would be inappropriate to subject patients with a flare of osteoarthritic pain to the placebo treatment for 12 weeks, and thus the study is designed as an active-comparator study.

Detailed description:

Arms:
arm 1: Etoricoxib, 30 mg tablet, orally, once daily for 12 weeks. arm 2: Celecoxib, 200 mg capsule, orally, once daily for 12 weeks.

Interventions: intervention 1: Etoricoxib 30 mg intervention 2: Celecoxib 200 mg
Intervention descriptions: intervention 1: Etoricoxib 30 mg tablet once daily for 12 weeks. intervention 2: Celecoxib 200 mg once daily for 12 weeks

Protocol document: